Archives of medical research · 2025
Evaluation of the Pilot Human Papillomavirus Self-Sampling Program in Workplaces in Ciudad Juárez, Mexico.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Doubova Svetlana V, Contreras-Sánchez Saúl Eduardo, McClellan Sean P, Piña-Sánchez Patricia
Аннотация
OBJECTIVE: To examine cervical cancer screening (CCS) coverage and follow-up before and after the introduction of the workplace Human Papilloma Virus self-sampling pilot program (HPV-SS-PP) for female factory workers in Ciudad Juárez, Mexico and to compare HPV-SS with conventional cervical cytology screening using the Papanicolaou (Pap) smear method.
METHODS: A secondary analysis was conducted using the Instituto Mexicano del Seguro Social (IMSS) cancer registry, the HPV-SS-PP registry, and the IMSS affiliation database. The study focused on IMSS-affiliated working women aged 35-64 living in Ciudad Juárez. We examined trends in CCS coverage during the 38 months before and the first 12 months after the HPV-SS-PP. We also examined HPV prevalence and follow-up indicators for HPV-positive women.
RESULTS: The study found that 44.8% of factories and 42.7% of women accepted the HPV-SS-PP program, leading to an initial increase and subsequent slowdown in CCS coverage. The HPV-16/18 genotype prevalence was 5%, and the HPV-pool prevalence was 18.1%. Follow-up for cervical cytology among women testing positive for the HPV-pool was 39.7%. Colposcopy and histopathology follow-up for HPV-16/18 genotypes and HPV-pool were moderate to high (64.8 and 84.7% for colposcopy, 87.8 and 93.2% for histopathology follow-up, respectively).
CONCLUSION: The HPV-SS-PP requires improvements to increase working women's participation in CCS and ensure better follow-up of positive HPV results.
METHODS: A secondary analysis was conducted using the Instituto Mexicano del Seguro Social (IMSS) cancer registry, the HPV-SS-PP registry, and the IMSS affiliation database. The study focused on IMSS-affiliated working women aged 35-64 living in Ciudad Juárez. We examined trends in CCS coverage during the 38 months before and the first 12 months after the HPV-SS-PP. We also examined HPV prevalence and follow-up indicators for HPV-positive women.
RESULTS: The study found that 44.8% of factories and 42.7% of women accepted the HPV-SS-PP program, leading to an initial increase and subsequent slowdown in CCS coverage. The HPV-16/18 genotype prevalence was 5%, and the HPV-pool prevalence was 18.1%. Follow-up for cervical cytology among women testing positive for the HPV-pool was 39.7%. Colposcopy and histopathology follow-up for HPV-16/18 genotypes and HPV-pool were moderate to high (64.8 and 84.7% for colposcopy, 87.8 and 93.2% for histopathology follow-up, respectively).
CONCLUSION: The HPV-SS-PP requires improvements to increase working women's participation in CCS and ensure better follow-up of positive HPV results.